Key result
A novel sublingual tablet combining atenolol and nifedipine rapidly reduced systolic blood pressure from 179.93 to 121.76 mmHg within 1.5 hours in hypertensive rats, demonstrating a faster onset of action than marketed formulations.
Why the study?
Single-drug treatment is usually inadequate to achieve blood pressure goals in hypertension, prompting evaluation of combination therapy using sublingual tablets to provide immediate action and enhance absorption in emergency conditions.
Does a novel sublingual tablet formulation of atenolol and nifedipine improve pharmacokinetic parameters and reduce blood pressure more rapidly than pure drugs and marketed formulations in hypertensive rats?
Does a novel sublingual tablet formulation of atenolol and nifedipine improve pharmacokinetic parameters and reduce blood pressure more rapidly than pure drugs and marketed formulations in hypertensive rats?
Absolute Event Rate: 121.76% vs 121.73%
A novel sublingual tablet formulation of atenolol and nifedipine demonstrated faster drug release and more rapid blood pressure reduction in a hypertensive rat model compared to pure drugs and marketed formulations, suggesting potential utility for emergency hypertension management.
Hypertension is considered a major health problems globally affect millions of patient.Various study confirms that single drug treatment usually is not adequate to achieve blood pressure goal in most hypertensive patients.In this regard,consideration is given to combination therapy, which offers the potential advantages towards minimizing hypertension in a rapid manner and produces lower adverse effects.SLTs (Sublingual tablets) provides immediate action to enhanced absorption and bioavailability rate. Sublingual tablets are absorbed within the mucus membrane and directly reach in blood systemic circulation. The objective of this ongoing research focused on theatenolol (ATN)and nifedipine (NIF) combined drug deliveryin emergency condition of hypertension. Direct compression technique is used to formulate SLTsby taking different types and concentrations of superdisintegrantsCroscarmellose sodium (CCS) and Crospovidone (CP). Sublimating agents like camphor (CM) and thymol (TY)) also added for better result. FTIR and DSC analysis confirms the ccompatibility results between drug and superdisintegrants.Formulated tablets are evaluated for different parameters and found satisfactory. Formulation F6 considered as the best formulation. The disintegration shows 13 sec and dissolution profile shows 97.36% drug release at 10 min. Formulation F6 shows better pharmacokinetic activity and antihypertensive activity in compare to pure drug and marketed formulation.A combination of ATN and NIF produces rapid disintegration and dissolution property during an emergency and is a lifesaving approach in hypertension treatment.
No takes yet. Share an insight, caveat, or question.
Swapna et al. (2021) studied Hypertension (n=24). Atenolol and Nifedipine combination sublingual tablet (Formulation F6) vs. Marketed antihypertensive tablets and pure drugs was evaluated on Reduction in systolic blood pressure. A novel sublingual tablet combining atenolol and nifedipine rapidly reduced systolic blood pressure from 179.93 to 121.76 mmHg within 1.5 hours in hypertensive rats, demonstrating a faster onset of action than marketed formulations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: